Format

Send to

Choose Destination
N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7.

Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Author information

1
From Harvard Medical School and Divisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women's Hospital - both in Boston (B.M.E.); the Department of Medicine, Alpert Medical School, and the Department of Health Services, Policy, and Practice, School of Public Health, Brown University; and Ocean State Research Institute, Providence VA Medical Center - all in Providence, RI (R.J.S.); and the Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, and CPC Clinical Research - both in Aurora (W.R.H.). All three authors participated as voting members of the FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on alirocumab, and Drs. Smith and Hiatt participated as voting members of the Advisory Committee meeting on evolocumab.
PMID:
26444323
DOI:
10.1056/NEJMp1508120
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center